NCT01908387View on ClinicalTrials.gov

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaAcute Myeloid LeukemiaMultiple MyelomaNon-Hodgkin LymphomaHodgkin Lymphoma
Interventions
DRUG

Oral azacitidine

100 mg to 300 mg oral azacitidine once daily for 14 days or 21 days of the initial 28-day cycle

Trial Locations (3)

277-8577

National Cancer Center Hospital East, Kashiwa

104-0045

National Cancer Center Hospital, Tokyo

135-8550

The Cancer Institute Hospital of JFCR, Tokyo

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY